

Covalon Announces Promotion of Kim Crooks to Chief Operating Officer and Appointment to Board of Directors

MISSISSAUGA, Ontario – May 15, 2025 – (BUSINESS WIRE) – Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is pleased to announce the promotion of Ms. Kim Crooks to the position of Chief Operating Officer (COO), effective immediately. In addition to her new role, Ms. Crooks has been appointed to Covalon's Board of Directors.

Ms. Crooks rejoined Covalon in early 2024 as Senior Vice President – Operations, bringing with her a wealth of experience from her previous tenure as Vice President of Operations at Covalon from 2012 to 2022. In her role as SVP, she has been instrumental in overseeing production, operations, Quality Assurance, Quality Control, Regulatory Affairs, and Human Resources.

Brent Ashton, Chief Executive Officer of Covalon Technologies Ltd., stated, "Kim has done an outstanding job leading our operations since rejoining Covalon at the beginning of 2024. Her leadership has been pivotal in enhancing our operational efficiency and aligning our processes with our strategic objectives. I could not be more excited for Kim to take on this expanded role as COO and to join our Board of Directors. Her deep understanding of our operations and commitment to the growth of our company make her an invaluable asset to our leadership team and Board of Directors."

Ms. Crooks will be granted 150,000 stock options that will vest equally over three years at an exercise price equal to the market price of the Company's common shares at the date of grant.

Ms. Crook's appointment to Covalon's Board of Directors and stock option grant are subject to the approval of the TSX Venture Exchange.

Those interested in learning about Covalon's solutions may visit www.covalon.com or follow Covalon on [LinkedIn](#), [Facebook](#), [Instagram](#), or [X](#).

To learn more about Covalon, please contact:

Investor Relations, Covalon Technologies Ltd.
Email: investors@covalon.com
Website: <https://covalon.com/>

About Covalon

Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at www.covalon.com.



Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might", "will" or "will be taken", "occur", or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at www.sedarplus.ca, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.

SOURCE Covalon Technologies Ltd.